Home | Structured Search | Drug Resource
Find: within
Dengue > Non-drug Therapy Author: Suranjith L. Seneviratne, MD, DPhil, MRCP, FRCPath; Panduka Karunanayake, MD, MRCP; Bandula Wijesiriwardena, MD, FRCP, FCCP, FCMSA, FRACP, FACP
Editorial changes - 2009-11-13
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • Vascular permeability resulting in plasma leakage is the main reason for circulatory compromise or shock in patients with severe dengue.
  • Administration of adequate crystalloids or colloids should result in normalization of intravascular volume.
  • The presence of significant external or internal bleeding is indicated by the failure of the blood pressure to increase despite a decline in hematocrit after adequate crystalloid or colloid administration.

Evidence:

  • The specific recommendations are based on WHO guidelines on the management of dengue fever and dengue hemorrhagic fever (55).

Comments:

  • Blood transfusion is indicated only in patients with significant hemorrhagic manifestations.
  • It may be difficult to recognize internal hemorrhage if there is hemoconcentration.
  • A decrease in hematocrit (e.g., from 0.5 [50%] to 0.4 [40%]) without clinical improvement despite the administration of sufficient fluids indicates significant internal hemorrhage.
  • Fresh whole blood is preferable, and the volume of blood administered should be sufficient to only increase the erythrocyte concentration to normal (i.e., 10 mL/kg·h).

FAQs
Bandula Wijesiriwardena, MD, FRCP, FCCP, FCMSA, FRACP, FACP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Panduka Karunanayake, MD, MRCP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Suranjith L. Seneviratne, MD, DPhil, MRCP, FRCPath has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.